Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Johnson & Johnson Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Joaquin Duato

İcra Kurulu Başkanı

US$13.1m

Toplam tazminat

CEO maaş yüzdesi	11.4%
CEO görev süresi	2yrs
CEO sahipliği	0.01%
Yönetim ortalama görev süresi	4.8yrs
Yönetim Kurulu ortalama görev süresi	4.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Joaquin Duato'un ücretlendirmesi Johnson & Johnson'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Oct 01 2023	n/a	n/a	US$14b
Jul 02 2023	n/a	n/a	US$14b
Apr 02 2023	n/a	n/a	US$13b
Jan 01 2023	US$13m	US$1m	US$18b
Oct 02 2022	n/a	n/a	US$18b
Jul 03 2022	n/a	n/a	US$17b
Apr 03 2022	n/a	n/a	US$20b
Jan 02 2022	US$14m	US$1m	US$21b
Oct 03 2021	n/a	n/a	US$18b
Jul 04 2021	n/a	n/a	US$18b
Apr 04 2021	n/a	n/a	US$15b
Jan 03 2021	n/a	n/a	US$15b
Sep 27 2020	n/a	n/a	US$17b
Jun 28 2020	n/a	n/a	US$15b
Mar 29 2020	n/a	n/a	US$17b
Dec 29 2019	US$13m	US$970k	US$15b
Sep 29 2019	n/a	n/a	US$14b
Jun 30 2019	n/a	n/a	US$16b
Mar 31 2019	n/a	n/a	US$15b
Dec 30 2018	US$9m	US$934k	US$15b
Sep 30 2018	n/a	n/a	US$2b
Jul 01 2018	n/a	n/a	US$1b
Apr 01 2018	n/a	n/a	US$1b
Dec 31 2017	US$19m	US$897k	US$1b

Tazminat ve Piyasa: Joaquin 'nin toplam tazminatı ($USD 13.10M ), AR pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.68M ).

Tazminat ve Kazançlar: Joaquin 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Joaquin Duato (60 yo)

2yrs

Görev süresi

US$13,099,487

Tazminat

Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joaquin Duato	CEO & Chairman	2yrs	US$13.10m	0.013% ARS 40.9b
Joseph Wolk	Executive VP & CFO	5.5yrs	US$8.82m	0.0022% ARS 7.0b
Jennifer Taubert	Executive VP & Worldwide Chairman of Innovative Medicine	12yrs	US$8.78m	0.0059% ARS 18.8b
Robert Decker	Controller & Chief Accounting Officer	4.1yrs	Veri yok	0.00073% ARS 2.3b
James Swanson	Executive VP & Chief Information Officer	4.2yrs	Veri yok	0.00038% ARS 1.2b
Jessica Moore	Vice President of Investor Relations	2.2yrs	Veri yok	Veri yok
Dirk Brinckman	Chief Compliance Officer	no data	Veri yok	Veri yok
Elizabeth Forminard	Executive VP & General Counsel	1.3yrs	Veri yok	0.00023% ARS 738.9m
Peter Fasolo	Executive VP & Chief Human Resources Officer	7.8yrs	US$3.62m	0.0043% ARS 13.7b
Guy Lebeau	Group Chairman of MD&D Business - EMEA	no data	Veri yok	Veri yok
William Hait	Executive VP	17yrs	Veri yok	0.0036% ARS 11.6b
Kathryn Wengel	Executive VP and Chief Technical Operations & Risk Officer	5.5yrs	Veri yok	0.0027% ARS 8.8b

4.8yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: DJNJ2 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joaquin Duato	CEO & Chairman	2yrs	US$13.10m	0.013% ARS 40.9b
D. Davis	Independent Director	9.6yrs	US$350.00k	Veri yok
Anne Mulcahy	Lead Independent Director	15yrs	US$410.00k	0.00033% ARS 1.1b
Hubert Joly	Independent Director	4.1yrs	US$340.00k	0.00021% ARS 674.7m
Marillyn Hewson	Independent Director	4.8yrs	US$353.59k	0.00012% ARS 385.5m
Paula Johnson	Independent Director	less than a year	Veri yok	0% ARS 0
Mark McClellan	Independent Director	10.3yrs	US$320.00k	Veri yok
Mary Beckerle	Independent Director	8.6yrs	US$360.00k	Veri yok
Darius Adamczyk	Independent Director	1.9yrs	US$300.16k	0.000040% ARS 128.5m
Jennifer Doudna	Independent Director	5.8yrs	US$340.00k	Veri yok
Mark Weinberger	Independent Director	4.1yrs	US$340.00k	Veri yok
Nadja West	Independent Director	3.1yrs	US$340.00k	Veri yok

4.4yrs

Ortalama Görev Süresi

62.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: DJNJ2 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.4 yıldır).

Johnson & Johnson Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Johnson & Johnson Announces Executive Changes

Recent updates

Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson

Johnson & Johnson Announces Positive Results from the Phase 2/3 Vibrance-MG Study of Nipocalimab

Johnson & Johnson Announces Tremfya Data in Both Crohn's Disease and Ulcerative Colitis

Johnson & Johnson Announces the Results of A Landmark Real-World, Head-To-Head Study Showing That Erleada (Apalutamide)

Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned

Johnson & Johnson Announces Data from Three Studies Highlighting Clinical Efficacy of Darzalex® (Daratumumab) and Darzalex Faspro in Maintenance Regimens

Johnson & Johnson Announces Interim Data from the Ongoing Phase 2 Sunrise-4 Study Showing Neoadjuvant Treatment with Investigational Tar-200 Plus Cetrelimab

Johnson & Johnson Announces Updated Results from the Phase 3 Mariposa-2 Study Which Showed Rybrevant (Amivantamab-Vmjw)

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025

Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis

Johnson & Johnson Announces Executive Changes

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib)

Johnson & Johnson Announces Results from the Phase 2 Open-Label UNITY Study of Nipocalimab for the Treatment of Alloimmunized Pregnant Individuals

Johnson & Johnson Announces Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj)-Based Quadruplet Regimen Approved in the U.S. for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible

Johnson & Johnson Seeks U.S. FDA Approval of Spravato (Esketamine) as the First and Only Monotherapy for Adults with Treatment-Resistant Depression

Johnson & Johnson Announces Quarterly Cash Dividend for Third Quarter of 2024, Payable on September 10, 2024

Johnson & Johnson Announces Positive Results from Prespecified Second Interim Analysis of the Phase 3 CARTITUDE-4 Study Evaluating CARVYKTI

Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş